Lack of insurance accounts for significant proportion of racial, ethnic disparities in stage III to IV diagnoses across range of cancers.

In this study, the CR rate with atezolizumab was 28.6, and at 12 months, the PFS was 42.9% and OS was 64.3%. These results suggest “that this chemotherapy-free regimen could become a new first-line ...

Physical function assessments with TUG and SPPB did not identify a decline in function among patients with CRPC receiving darolutamide over 24 weeks.

The 5-year disease-free survival rate was 63.3% for patients with microsatellite instability and 41.4% for patients with microsatellite-stable disease. Microsatellite instability (MSI) is a “striking” ...

Researchers estimated worldwide epidemiological trends in melanoma from 1990 to 2021, including incidence, mortality, and disability adjusted life years.

Chemotherapy was associated with short-term cognitive dysfunction after treatment completion among patients with breast cancer. These findings were published in The Oncologist. Chemotherapy-induced ...

Researchers sought to determine whether DNA methylation markers could be helpful in risk stratification for patients with AML and normal cytogenetics.

Researchers sought to determine the effects of multidisciplinary team-style continuity of care with nutritional nursing in patients with lung cancer receiving postoperative chemotherapy.

Cancer patients who received psilocybin-assisted psychotherapy experienced improvements in anxiety, depression, interpersonal sensitivity, hostility, obsession-compulsion, and somatization. Psilocybin ...

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

Patients with abnormal numbers of CD3 + T cells had considerably higher mortality and recurrence rates. The immune system and especially the B cells of patients with acute lymphoblastic leukemia (ALL) ...

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.